Time filter

Source Type

Thessaloníki, Greece

Kaprara A.,Anticancer Hospital Theagenio | Pazaitou-Panayiotou K.,Anticancer Hospital Theagenio | Kortsaris A.,Democritus University of Thrace | Chatzaki E.,Democritus University of Thrace
Cellular and Molecular Life Sciences | Year: 2010

Malignant tumors express multiple factors that have some role in the regulating networks supporting their ectopic growth. Recently, increased interest has been developing in the expression and biological role of the neuropeptides and receptors of the corticotropin releasing factor (CRF) system, the principal neuroendocrine mediator of the stress response, especially in the light of several R&D programs for small molecule antagonists that could present some anticancer therapeutic benefit. In the present article, we review the literature suggesting that the CRF system could be involved in the regulation of human cancer development. Potential implication in growth, metastasis, angiogenesis, or immune parameters via activation of locally expressed receptors could be clinically exploited by presenting targets of new therapeutic approaches. © Birkhäuser Verlag.

Kaprara A.,Anticancer Hospital Theagenio | Pazaitou-Panayiotou K.,Anticancer Hospital Theagenio | Chemonidou M.C.,Democritus University of Thrace | Constantinidis T.C.,Laboratory of Hygiene | And 6 more authors.
Neuropeptides | Year: 2010

The hypothalamic neuropeptide corticotropin releasing factor (CRF) has been found in several types of human cancer, where its biological role is not clarified. In experimental models of breast cancer CRF has been shown to exert anti-proliferative and other actions. Aim of the present study was to describe the expression of the two types of CRF receptors CRF1 and CRF2 in human breast tumors. Receptor expression was studied in breast biopsies from patients diagnosed for primary breast adenocarcinoma, obtained from the tumor and the adjacent benign tissue. Gene expression levels were evaluated by real-time PCR following reverse transcription of total RNA extracts. CRF1 transcripts were found in 23.1% of benign and in 23.1% of malignant biopsies. CRF2(a) was found in 22.2% of benign and 36.0% of malignant biopsies. Transcript levels of both receptors did not differ significantly between cancer and benign biopsies from the same tumor. No correlation was found between CRF receptor expression and patient histo/clinicopathological characteristics. Histological mapping using immunohistochemistry revealed positive CRF1 immunostaining in the cancerous implants and breast ducts, whereas CRF2 immunoreactivity was localized mainly in the perineural invasions. In conclusion, both CRF receptors were found in breast cancer and the respective benign adjacent tissue. The two CRF receptor proteins presented distinct distribution and subcellular localization, pointing into differing biological roles. CRF receptors could serve as targets of endogenous ligands expressed in the tumor microenvironment, regulating cancer growth. © 2010 Elsevier Ltd.

Discover hidden collaborations